Two clinical trials have been completed with enadenotucirev. The EVOLVE study and the MOA study. , there are two active
phase 1 trials: OCTAVE (in
ovarian cancer) and SPICE (in multiple solid tumor indications) Of the T-SIGn viruses, NG-350A has an ongoing clinical study. ==See also==